ClinicalTrials.gg
RecruitingNCT03832127MyelofludateUpdated Nov 13, 2026

Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients

A Phase 1 interventional study of 18F-Fludarabine in Myeloma, sponsored by Nantes University Hospital. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nantes University Hospital · Phase 1, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.
Updated Nov 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 47 studies in Neoplasms, Plasma Cell with a site in France — 7 open to participants now, 10 under way, 2 of them phase 3. Neoplasms, Plasma Cell · France.

Planned enrollment
34th of 37
35 · median 120
Started
2022
with 4 others
Phase 1
5 of 47
2 open now
Registered
25th of 47
by date
Lead sponsor
3 of 47
Nantes University Hospital

Among the 47 studies in Neoplasms, Plasma Cell with a site in France, this one is the 34th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2022, is one of 5 in phase 1, and was the 25th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

7 of the 47 studies in Neoplasms, Plasma Cell with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Neoplasms, Plasma Cell with a site in France, or all of them as a file.
02

Study summary

The objective of this exploratory study is to evaluate, for the first time, the sensitivity of 18F-Fludarabine to the initial diagnosis of MM compared to FDG-PET and MRI. The interest of this molecule will also be investigated as part of the end-of-treatment therapeutic evaluation.

03

Conditions studied

  • Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic MM in the in patients who are not candidates for bone marrow transplantation.
  • Patients eligible for one of the treatments considered as standard in a patient who is not eligible for autograft, according to ESMO's European recommendations
  • MM with either by the serum evaluation of the monoclonal component or by the determination of free light chains (serum or urinary).
  • Patient affiliated with a social insurance scheme
  • The patient must understand and voluntarily sign the form
  • Women of must have a serum pregnancy test (performed within 2 days before each PET scan.)
  • Women of childbearing potential must use an effective method throughout the course of the study and for 30 days after the last PET.
  • Male patients (vasectomised or not) with a pregnant partner or a partner of childbearing potential must use a condom and a spermicide until 90 days after the last PET.
  • serology known to be negative
  • ≥ 70 or 0-1

Exclusion criteria

Exclusion Criteria:

  • Age under 18 years
  • Pregnancy or breastfeeding
  • Male or female refusing conditions
  • Primary AL amyloidosis and myeloma complicated by amyloidosis
  • Neutropenia \<1000 PN / mm3
  • Thrombocytopenia \<70,000 / mm3
  • Hepatic impairment: > 35μmol / L and , SGPT, alkaline phosphatase greater than 3 N
  • Renal impairment defined by \<50 ml / min
  • History of other with the exception of basal cell carcinoma and stage I cervical cancer
  • Severe active infection
  • Active infection with known or C virus.
  • Patient with insulin-dependent or non-insulin-dependent diabetes mellitus.
  • Intolerance or known allergy to any of the study drugs or any of its analogues
  • Psychiatric illness that may interfere with participation in the study
  • Patient under safeguard of justice
  • Intellectual inability to sign
  • Persons protected by law
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Fludatep

    PET with 18F-Fludarabine

    Drug: 18F-Fludarabine

Interventions

  • Drug18F-Fludarabine

    Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma

06

What researchers measure

Primary outcomes

  1. Detection of sensitivity of the lesions (osseous and extra-osseous) of 18Fludarabine PET (FludaTEP)

    The sensitivity of the initial FludaTEP will be evaluated using an optimal reading mode lesion analysis (ie by consensus of experts) by defining : True positive: * positive lesion with 18F-Fludarabine and positive with PET-FDG or MRI * or positive lesion with 18-F-Fludarabine, negative with PET-FDG and MRI, but confirmed by further complementary imaging (CT) or histological examination, or confirmed at follow-up False negative: -negative lesion with 18F-Fludarabine and positive FDG-PET and / or MR Lesions positivity in PET-FDG and MRI will be assessed by central reading done by consensus of experts. Lesions positivity with 18F-Fludarabine will be defined by central reading assessed by 2 nuclear physicians experts in hematology with no access to the other exams' results.

    Time frame: Before treatment

Secondary outcomes

  1. To evaluate the specificity and the positive and negative predictive values of the FludaTEP for the initial assessment through an optimal reading mode.

    The specificity, positive predictive value (PPV) and negative predictive value (NPV) of the FludaTEP for the initial assessment will be assessed through an optimal reading mode lesion analysis (ie by consensus of experts) using same true positive and false positive définitions as for the main endpoint and defining: -positive lesion with 18F-Fludarabine but not found or confirmed on an histological examination, or other imaging technique (PET-FDG, MRI +/- Scan) or at follow-up True negative: -negative lesion with 18F-Fludarabine and negative with FDG-PET and MRI

    Time frame: Before treatment

  2. To evaluate the sensitivity, specificity, and positive and negative predictive values of the FludaTEP for the initial balance according to the local reading

    The specificity, positive predictive value (PPV) and negative predictive value (NPV) of the FludaTEP for the initial balance will be evaluated through lesion analysis based on the local reading investigator center reading using definitions of VP, VN, FP, and FN described above.

    Time frame: Before treatment

  3. To evaluate the prognostic impact of FDG-PET and FludaTEP on the number of lesions detected by each imaging technique in a population of MM patients in the 1st line therapeutic but not candidates for marrow autograft.

    The prognostic impact of FDG-PET and FludaTEP as a function of the number of lesions detected by each imaging technique will be evaluated by evaluating the impact of these data on progression-free survival and overall survival. Progression-free survival is defined as the time between the beginning of treatment of the disease and relapse or progression. Overall survival is defined as the time between the start of treatment and death.

    Time frame: After treatment

  4. To evaluate the prognostic impact of FludaTEP on the initial assessment and for the end-of-treatment therapeutic evaluation

    The prognostic impact of FludaTEP on the initial assessment and for the end-of-treatment therapeutic evaluation will be determined by evaluating the impact of a decrease and a negation of the signal in imaging on an increase in progression-free survival and overall survival.

    Time frame: Before and After treatment

  5. Evaluate in a population of MM patients the existence of a correlation between the 18Fludarabine and FDG uptake intensities

    Correlations between the 18Fludarabine and FDG uptake intensities assessed by SUVs and the quantitative expression of markers measured in flow cytometry and cytogenetic data (in particular the expression of the coding gene for hexokinases) will be measured using Spearman's correlation coefficient.

    Time frame: Before and After treatment

  6. Evaluate in a population of MM patients the existence of a correlation between the 18Fludarabine and FDG uptake intensities and the cytogenetic data Tolerance to 18F-Fludarabine

    Tolerance to 18F-Fludarabine will be evaluated by clinical monitoring during 2 hours following the 18F-Fludarabine injection. Clinical data will be taken prior to the 18F-Fludarabine injection, prior to the data capture at 60min and after the last data capture.

    Time frame: Before and After treatment

07

Study locations

5 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2029, 84 months after the start.

Of 35 non-industry phase 1 interventional studies under Neoplasms, Plasma Cell, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 96. This study's planned 84 months is above that.

Counting every sponsor, half of 51 studies reached it within 61 months; a quarter within 27 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2024 → Sep 2029 and completion Sep 2026 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2018
First posted
Feb 6, 2019
StartActual
Sep 7, 2022
Primary completionEst.
Sep 7, 2029was Sep 2024
CompletionEst.
Sep 7, 2029was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 9, 2022→Sep 7, 2022
Nov 13, 2026
Primary completion
Sep 9, 2024→Sep 7, 2029
Nov 13, 2026
Study completion
Sep 9, 2026→Sep 7, 2029
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Sep 9, 2022→Sep 7, 2022
    Primary completion Sep 9, 2024→Sep 7, 2029
    Study completion Sep 9, 2026→Sep 7, 2029
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03832127
Collaborators
Cyceron
Responsible party
Sponsor
First posted
Feb 6, 2019
Start date
Sep 7, 2022
Primary completion
Sep 7, 2029 (estimated)
Completion
Sep 7, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Caroline Bodet-Milin, MD
Contact
caroline.milin@chu-nantes.fr
33240084136

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion